| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | 0.12 | 0.5 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.5 |